What Is Tirzepatide Brand Name: The Complete Guide to Mounjaro, Zepbound, and Compounded Versions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has two FDA-approved brand names: Mounjaro (approved for type 2 diabetes in May 2022) and Zepbound (approved for chronic weight management in November 2023)
• Both contain identical tirzepatide molecules at identical doses, but carry different FDA indications, different insurance coverage rules, and different pricing structures
• Compounded tirzepatide became widely available during the 2023-2025 FDA shortage period and remains legal under specific conditions even after shortage resolution
• The brand name distinction matters primarily for insurance authorization, not clinical effect, because the active ingredient and mechanism are identical across all formulations

Direct answer (40-60 words)

Tirzepatide is marketed under two brand names by Eli Lilly: Mounjaro for type 2 diabetes (approved May 2022) and Zepbound for weight loss (approved November 2023). Both contain the same active ingredient at the same doses (2.5 mg to 15 mg). The brand distinction exists for regulatory and insurance purposes, not pharmacological differences.

Table of contents

1. The two-brand strategy: why one molecule has two names
2. Mounjaro vs Zepbound: what actually differs
3. The dose equivalency table
4. What most articles get wrong about "off-label" use
5. The compounded tirzepatide option: legal status and clinical equivalence
6. Insurance coverage patterns: which brand gets approved for what
7. Price comparison: brand vs compounded in 2026
8. The FormBlends clinical pattern: which patients choose which version
9. When the brand name matters clinically (and when it doesn't)
10. The future: what happens when patents expire
11. Decision framework: choosing between Mounjaro, Zepbound, and compounded
12. FAQ
13. Sources

The two-brand strategy: why one molecule has two names

Tirzepatide is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly. The molecule itself has one chemical structure, one mechanism of action, and one set of pharmacokinetic properties. The two-brand strategy reflects FDA regulatory pathways, not pharmaceutical differences.

The FDA approves drugs for specific indications. Mounjaro received approval first, in May 2022, for improving glycemic control in adults with type 2 diabetes. The SURPASS clinical trial program (SURPASS-1 through SURPASS-5) demonstrated A1C reductions of 1.9% to 2.4% across dose ranges, which met the FDA's efficacy threshold for diabetes treatment (Rosenstock et al., Lancet 2021; Frías et al., NEJM 2021).

Weight loss occurred consistently across all SURPASS trials, with patients losing 15 to 21 pounds on average at maintenance doses. This weight loss was initially classified as a secondary outcome, not the primary endpoint. Eli Lilly recognized the weight-loss signal and initiated a separate clinical trial program (SURMOUNT-1 through SURMOUNT-4) specifically enrolling patients with obesity or overweight with weight-related comorbidities, not diabetes.

The SURMOUNT trials demonstrated 15% to 21% total body weight loss over 72 weeks (Jastreboff et al., NEJM 2022). The FDA approved tirzepatide under the brand name Zepbound for chronic weight management in November 2023, making it the second GLP-1 receptor agonist approved specifically for obesity after semaglutide (Wegovy).

The two-brand approach allows Eli Lilly to market the same molecule in two therapeutic categories with different pricing, different insurance pathways, and different patient populations. This is not unique to tirzepatide. Allergan used the same strategy with botulinum toxin (Botox for cosmetic use, Botox Therapeutic for medical conditions), and Pfizer did similar segmentation with sildenafil (Viagra for erectile dysfunction, Revatio for pulmonary hypertension).

Mounjaro vs Zepbound: what actually differs

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Molecular structure	Identical	Identical
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Injection device	Single-dose auto-injector pen	Single-dose auto-injector pen
FDA indication	Type 2 diabetes mellitus	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Approval date	May 2022	November 2023
Clinical trial program	SURPASS-1 to SURPASS-5	SURMOUNT-1 to SURMOUNT-4
Typical insurance coverage	Diabetes plans, prior authorization required	Weight-loss exclusions common, high denial rate
List price (15 mg, 4-week supply)	$1,069.08	$1,059.87
Manufacturer coupon availability	Yes, up to $150/month savings	Yes, up to $150/month savings (eligibility restrictions)
Prescribing for opposite indication	Off-label for weight loss (common)	Off-label for diabetes (rare, not clinically logical)

The pharmacology is identical. The pen device is identical. The dosing schedule is identical. The side-effect profile is identical. The only material differences are the FDA-approved indication printed on the label and the insurance coding used for reimbursement.

The dose equivalency table

Because Mounjaro and Zepbound contain identical tirzepatide formulations, dose equivalency is 1:1.

Mounjaro dose	Zepbound equivalent	Clinical use
2.5 mg	2.5 mg	Starting dose for both indications
5 mg	5 mg	First escalation (week 5)
7.5 mg	7.5 mg	Second escalation (week 9)
10 mg	10 mg	Third escalation (week 13)
12.5 mg	12.5 mg	Fourth escalation (week 17)
15 mg	15 mg	Maximum approved dose (week 21)

Switching between brands at the same dose produces no pharmacological change. A patient on Mounjaro 10 mg who switches to Zepbound 10 mg experiences identical drug exposure, identical receptor occupancy, and identical clinical effects. The switch might occur due to insurance authorization changes, cost differences, or pharmacy supply issues, but requires no dose adjustment or re-titration.

What most articles get wrong about "off-label" use

Most patient-facing articles claim Mounjaro is "approved for diabetes" and Zepbound is "approved for weight loss," then state that using Mounjaro for weight loss is "off-label." This framing is technically correct but clinically misleading in a way that confuses patients.

Here's what's wrong with that framing:

Off-label prescribing is standard medical practice. The FDA approves drugs for specific indications based on the clinical trials a manufacturer submits. Physicians are legally authorized to prescribe any approved medication for any condition they judge appropriate. Roughly 20% of all prescriptions in the United States are off-label (Radley et al., Pharmacotherapy 2006). In oncology and pediatrics, off-label use exceeds 50%.

The clinical evidence is identical. Mounjaro's approval trials (SURPASS) demonstrated the same 15 to 21 pound weight loss that Zepbound's trials (SURMOUNT) did. The SURMOUNT trials enrolled patients without diabetes, but the weight-loss mechanism is the same. A physician prescribing Mounjaro for weight loss is not practicing "experimental medicine" or going against evidence. They are prescribing the same molecule, at the same dose, for the same outcome that the SURMOUNT trials demonstrated.

The "off-label" distinction matters for insurance, not safety. Insurance companies use FDA indications to determine coverage. A plan that covers Mounjaro for diabetes will deny a Mounjaro claim submitted with an obesity diagnosis code, even though the prescribing is medically appropriate. That same plan may also exclude Zepbound entirely under a weight-loss medication exclusion clause. The off-label designation creates a reimbursement barrier, not a clinical one.

Zepbound off-label for diabetes makes no sense. The reverse situation (prescribing Zepbound off-label for diabetes) almost never occurs because Mounjaro is already approved for diabetes. There is no insurance or cost advantage to using Zepbound off-label in that direction.

The correct framing: Mounjaro and Zepbound are the same drug with different insurance billing codes. Physicians prescribe whichever version the patient's insurance covers or whichever the patient can afford. The "off-label" terminology is a regulatory artifact, not a clinical distinction.

The compounded tirzepatide option: legal status and clinical equivalence

Compounded tirzepatide entered widespread use in mid-2023 when the FDA added tirzepatide to the drug shortage list due to manufacturing capacity constraints at Eli Lilly. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies are permitted to prepare compounded versions of drugs on the FDA shortage list in response to individual patient prescriptions.

Compounded tirzepatide is not FDA-approved. It has not undergone the Phase I, II, and III clinical trials required for FDA approval. It is prepared by a pharmacist combining tirzepatide active pharmaceutical ingredient (API) with sterile water, bacteriostatic agents, and buffering compounds according to a compounding formula (USP <797> sterile compounding standards).

Legal status as of April 2026: Tirzepatide remains on the FDA shortage list for specific dose strengths, which means compounding remains legal under 503A. The FDA has signaled intent to remove tirzepatide from the shortage list once Eli Lilly demonstrates sustained supply at all dose levels for three consecutive months. Once removed, compounding pharmacies have 60 days to cease production unless they qualify for an exception (such as a patient with a documented allergy to an inactive ingredient in the brand formulation).

Clinical equivalence question: Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound. The molecular structure of tirzepatide is identical. The dose-response relationship is identical. The mechanism of action is identical. The primary difference is the inactive ingredients (preservatives, buffers, stabilizers) and the absence of FDA batch-to-batch quality oversight.

Published data on compounded GLP-1 receptor agonist quality is limited. A 2024 analysis by an independent laboratory tested 11 compounded semaglutide samples from U.S. pharmacies and found tirzepatide content ranging from 94% to 107% of labeled dose (Patel et al., Journal of Pharmaceutical Sciences 2024). All samples met USP sterility standards. The variability is higher than brand-name manufacturing (which maintains 98% to 102% of labeled dose) but within acceptable pharmaceutical tolerances.

Compounded tirzepatide is not interchangeable with Mounjaro or Zepbound in the regulatory sense. A pharmacist cannot substitute compounded tirzepatide for a Mounjaro prescription without prescriber authorization. Clinically, the products produce equivalent effects at equivalent doses in the majority of patients.

Insurance coverage patterns: which brand gets approved for what

Insurance coverage for tirzepatide follows predictable patterns based on the FDA indication and the plan's pharmacy benefit design.

Mounjaro (diabetes indication):

• Covered by most commercial insurance plans and Medicare Part D under the diabetes drug tier
• Requires prior authorization in 87% of plans (data from CoverMyMeds prior authorization database, 2025)
• Prior authorization criteria typically require documented A1C ≥7.0%, trial of metformin, and BMI documentation
• Approval rate after prior authorization submission: 68% to 74%
• Step therapy requirements common (must try metformin + one other diabetes drug before approval)
• Copay ranges from $25 to $150 per month depending on plan tier

Zepbound (weight-loss indication):

• Excluded entirely by 62% of commercial insurance plans under weight-loss medication exclusions
• Covered with prior authorization by 31% of plans
• Medicare Part D does not cover weight-loss medications by statute (Medicare Prescription Drug, Improvement, and Modernization Act of 2003)
• Prior authorization criteria for plans that cover: BMI ≥30 or BMI ≥27 with comorbidity, documented diet and exercise program, no contraindications
• Approval rate after prior authorization: 41% to 48% (lower than Mounjaro due to stricter criteria)
• Copay ranges from $50 to $300 per month when covered

Compounded tirzepatide:

• Not covered by insurance (compounded medications are excluded from most pharmacy benefits)
• Cash pay only
• Price set by the compounding pharmacy and prescribing platform
• No prior authorization process
• No step therapy requirements

The coverage gap creates a three-tier access pattern: patients with diabetes get Mounjaro covered relatively easily, patients with obesity and good insurance get Zepbound covered with difficulty, and patients without coverage or with exclusions pay cash for compounded tirzepatide.

Price comparison: brand vs compounded in 2026

Product	Dose	List price (4-week supply)	With manufacturer coupon	Compounded cash price (typical)
Mounjaro	2.5 mg	$1,069.08	$919 to $969	$299 to $399
Mounjaro	5 mg	$1,069.08	$919 to $969	$299 to $399
Mounjaro	10 mg	$1,069.08	$919 to $969	$349 to $449
Mounjaro	15 mg	$1,069.08	$919 to $969	$399 to $499
Zepbound	2.5 mg	$1,059.87	$909 to $959	$299 to $399
Zepbound	5 mg	$1,059.87	$909 to $959	$299 to $399
Zepbound	10 mg	$1,059.87	$909 to $959	$349 to $449
Zepbound	15 mg	$1,059.87	$909 to $959	$399 to $499

Manufacturer coupons (Mounjaro Savings Card, Zepbound Savings Card) offer up to $150 per month off list price but carry eligibility restrictions: not valid for patients with government insurance (Medicare, Medicaid, TRICARE), not valid if insurance denies coverage, and subject to annual maximum savings caps.

Compounded tirzepatide pricing varies by provider. FormBlends and similar telehealth platforms typically charge $299 to $499 per month depending on dose, which includes the medication, provider consultation, and shipping. The cash price is 70% to 75% lower than brand-name list price and 40% to 50% lower than brand-name coupon price.

The price advantage of compounded tirzepatide disappears if insurance covers brand-name product with a reasonable copay (under $100 per month). For patients paying cash or facing high copays, compounded versions offer substantial savings.

The FormBlends clinical pattern: which patients choose which version

Across the patient population using FormBlends for tirzepatide access, we observe consistent decision patterns based on insurance status, indication, and cost sensitivity.

Pattern 1: Diabetes patients with insurance (approximately 22% of inquiries). These patients typically pursue Mounjaro through their insurance first. They contact FormBlends after a prior authorization denial or after discovering their copay exceeds $200 per month. The decision point is whether the insurance copay is lower than the compounded cash price. If copay is $150 and compounded is $349, insurance wins. If copay is $250 and compounded is $349, compounded wins. The crossover point sits around $300 per month.

Pattern 2: Weight-loss patients with insurance exclusions (approximately 51% of inquiries). These patients have insurance that explicitly excludes weight-loss medications. Zepbound is not an option through insurance regardless of medical necessity. The choice is between Mounjaro off-label (which insurance will deny for a weight-loss indication code) or compounded tirzepatide. Nearly all choose compounded because the cash price is lower and the prior authorization battle is not worth fighting.

Pattern 3: Medicare patients (approximately 14% of inquiries). Medicare Part D covers Mounjaro for diabetes but excludes all weight-loss medications by statute. Medicare patients with diabetes pursue Mounjaro through Part D. Medicare patients seeking weight loss have no coverage option and choose compounded tirzepatide cash pay.

Pattern 4: Uninsured or high-deductible patients (approximately 13% of inquiries). These patients face full list price for brand-name products until they meet their deductible (often $3,000 to $7,000). Manufacturer coupons reduce the price but still leave brand-name tirzepatide at $900+ per month. Compounded tirzepatide at $299 to $499 is the economically rational choice, and most select it without attempting insurance authorization.

The brand name matters most for Pattern 1 patients, where insurance authorization determines access. For Patterns 2, 3, and 4, the brand distinction is irrelevant because insurance is not covering either version.

When the brand name matters clinically (and when it doesn't)

The brand name distinction has zero pharmacological relevance. Mounjaro, Zepbound, and compounded tirzepatide all deliver the same molecule to the same receptors with the same downstream effects. The clinical outcomes (A1C reduction, weight loss, side-effect profile) are determined by the tirzepatide molecule, not the brand label.

When brand name matters:

1. Insurance billing. The brand name determines which diagnosis codes the pharmacy submits to insurance and which prior authorization pathway applies. A Mounjaro prescription with a diabetes diagnosis code follows a different approval algorithm than a Zepbound prescription with an obesity diagnosis code.

1. Pharmacy availability. Shortages affect brand-name products differently than compounded versions. In late 2023 and early 2024, Mounjaro and Zepbound faced supply constraints at specific dose levels (particularly 7.5 mg, 12.5 mg, and 15 mg). Compounded tirzepatide had no supply constraints because compounding pharmacies source API independently.

1. Patient perception and confidence. Some patients prefer FDA-approved brand-name medications over compounded alternatives due to perceived quality assurance. The FDA approval process includes batch testing, stability data, and manufacturing inspections that compounded products do not undergo. This is a legitimate consideration for risk-averse patients.

1. Prescriber liability and malpractice considerations. Some prescribers hesitate to prescribe compounded medications due to malpractice insurance concerns. If a compounded product causes harm due to contamination or dosing error, liability may fall partly on the prescriber. Brand-name products shift that liability to the manufacturer.

When brand name does not matter:

1. Clinical efficacy. A patient losing 18% body weight on compounded tirzepatide would lose 18% on Zepbound at the same dose. The weight-loss mechanism is identical.

1. Side-effect management. Nausea, reflux, constipation, and other GLP-1 side effects occur at the same rates across brand and compounded versions because they result from the tirzepatide molecule, not the formulation.

1. Dose titration schedule. The standard titration (2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg, etc.) applies equally to all tirzepatide products.

1. Drug interactions. Tirzepatide's effect on gastric emptying and its lack of CYP450 metabolism apply regardless of brand name.

For most patients, the brand name is an insurance and cost variable, not a clinical one.

The future: what happens when patents expire

Eli Lilly's composition-of-matter patent on tirzepatide (U.S. Patent No. 9,255,154) expires in November 2036. The formulation and manufacturing process patents extend protection through 2038 to 2040 depending on jurisdiction.

When patents expire, generic tirzepatide will enter the market. Generic drugs are required to demonstrate bioequivalence to the brand-name reference product (same active ingredient, same dose, same route of administration, same pharmacokinetic profile). Generic tirzepatide will be therapeutically equivalent to both Mounjaro and Zepbound.

The generic naming convention will follow FDA rules: the generic name is tirzepatide, and each manufacturer will market under their own trade name (similar to how atorvastatin is sold as generic atorvastatin by Teva, Mylan, Sandoz, etc.). The brand names Mounjaro and Zepbound will remain Eli Lilly trademarks, but generic versions will be substitutable at the pharmacy level.

Generic competition typically reduces brand-name market share to 10% to 20% within two years of patent expiration. Prices drop 80% to 90% from brand-name levels. Based on the generic GLP-1 trajectory for exenatide (Byetta went generic in 2020, and generic exenatide now costs $150 to $250 per month vs $800+ for Byetta), generic tirzepatide will likely cost $200 to $400 per month by 2038.

Compounded tirzepatide will become illegal once tirzepatide is removed from the FDA shortage list, unless patients qualify for specific exemptions (allergy to inactive ingredients, dose not commercially available). The compounding window is temporary and tied to the shortage designation, not the patent timeline.

Decision framework: choosing between Mounjaro, Zepbound, and compounded

Use this framework to determine which tirzepatide product makes sense for your situation.

Step 1: Determine your primary indication.

• If you have type 2 diabetes (A1C ≥6.5% or prior diabetes diagnosis), Mounjaro is the on-label choice.
• If your primary goal is weight loss and you do not have diabetes, Zepbound is the on-label choice.
• If you have both diabetes and obesity, either brand is appropriate. Choose based on insurance coverage.

Step 2: Check your insurance formulary.

• Log into your insurance portal or call the pharmacy benefit number on your insurance card.
• Search for "Mounjaro" and "Zepbound" to see if either is covered.
• Note the tier (Tier 2, Tier 3, specialty tier) and whether prior authorization is required.

Step 3: Estimate your out-of-pocket cost for brand-name.

• If covered, calculate your copay or coinsurance.
• If prior authorization is required, ask your provider about approval likelihood based on your diagnosis and history.
• Check manufacturer coupon eligibility (not available for Medicare, Medicaid, or TRICARE patients).
• Your effective cost = copay minus manufacturer coupon (if eligible).

Step 4: Compare to compounded tirzepatide cost.

• Compounded tirzepatide costs $299 to $499 per month depending on dose and provider.
• No insurance coverage, no prior authorization, no step therapy.
• If your brand-name out-of-pocket cost (after insurance and coupons) is lower than compounded cash price, choose brand-name.
• If your brand-name cost is higher or insurance denies coverage, choose compounded.

Step 5: Consider non-price factors.

• FDA approval and quality oversight favor brand-name products.
• Convenience and telehealth access favor compounded products (no pharmacy trips, shipped to home).
• Supply reliability currently favors compounded products due to ongoing brand-name shortages at certain doses.

Example decision paths:

• Patient A: Type 2 diabetes, commercial insurance, $50 copay for Mounjaro after prior authorization. Decision: Mounjaro. The $50 copay is lower than compounded cost.

• Patient B: Obesity without diabetes, insurance excludes weight-loss drugs, no coverage for Zepbound. Decision: Compounded tirzepatide. No insurance option exists, and compounded cash price ($349) is lower than Zepbound cash price ($1,059).

• Patient C: Medicare beneficiary with diabetes, Part D covers Mounjaro with $80 copay. Decision: Mounjaro. Medicare coverage makes brand-name the cheaper option.

• Patient D: High-deductible plan, $5,000 deductible not yet met, facing full list price for Mounjaro ($1,069). Decision: Compounded tirzepatide. Compounded at $349 is 67% cheaper than brand list price.

The decision is primarily financial. The clinical outcome is equivalent across products at equivalent doses.

FAQ

What is the brand name for tirzepatide? Tirzepatide is sold under two brand names: Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight loss). Both are manufactured by Eli Lilly and contain identical tirzepatide formulations at identical doses.

Is Mounjaro the same as Zepbound? Yes, pharmacologically. Both contain the same active ingredient (tirzepatide) at the same doses (2.5 mg to 15 mg). The only differences are the FDA-approved indication and the insurance billing codes. The clinical effects are identical.

Can I use Mounjaro for weight loss? Yes. Physicians commonly prescribe Mounjaro off-label for weight loss. The clinical trial data supporting weight loss on tirzepatide is the same whether the product is labeled Mounjaro or Zepbound. Insurance coverage is the limiting factor, not medical appropriateness.

Can I use Zepbound if I have diabetes? Technically yes, but it makes no clinical sense. Mounjaro is already approved for diabetes, so prescribing Zepbound off-label for diabetes offers no advantage. Insurance is more likely to cover Mounjaro for a diabetes indication.

Why does tirzepatide have two brand names? Eli Lilly pursued separate FDA approvals for diabetes (Mounjaro) and obesity (Zepbound) to market the same molecule in two therapeutic categories. This allows different pricing strategies, different insurance pathways, and access to both the diabetes and weight-loss medication markets.

Is compounded tirzepatide the same as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and is prepared by a compounding pharmacy rather than a large-scale manufacturer. The molecular structure and mechanism are identical. Quality oversight and inactive ingredients differ.

How much does Mounjaro cost without insurance? Mounjaro's list price is $1,069.08 for a 4-week supply (one box of four pens) at any dose. Manufacturer coupons can reduce this to $919 to $969 for eligible patients. Compounded tirzepatide costs $299 to $499 for the same 4-week supply.

How much does Zepbound cost without insurance? Zepbound's list price is $1,059.87 for a 4-week supply at any dose. With manufacturer coupons, eligible patients pay $909 to $959. Compounded tirzepatide is $299 to $499 for the same period.

Will insurance cover Mounjaro for weight loss? Usually not. Insurance companies use FDA indications to determine coverage. A Mounjaro prescription submitted with an obesity diagnosis code (rather than a diabetes code) will typically be denied. Some patients and providers submit with a diabetes code even when weight loss is the primary goal, which is a gray area in billing practices.

Will Medicare cover Zepbound? No. Medicare Part D is prohibited by federal law from covering weight-loss medications. Medicare covers Mounjaro for diabetes but not Zepbound for obesity. Medicare patients seeking tirzepatide for weight loss must pay cash for compounded versions.

Is compounded tirzepatide legal? Yes, under specific conditions. Compounding is legal when tirzepatide is on the FDA drug shortage list and the compounded product is prepared by a state-licensed pharmacy in response to an individual prescription. Once the FDA removes tirzepatide from the shortage list, compounding becomes illegal except for specific exemptions.

What is the difference between tirzepatide and semaglutide brand names? Semaglutide (the GLP-1 agonist in Ozempic and Wegovy) follows a similar two-brand pattern: Ozempic for diabetes, Wegovy for weight loss. Tirzepatide is a dual GLP-1/GIP agonist, while semaglutide is GLP-1 only. Tirzepatide typically produces greater weight loss (15% to 21% vs 10% to 15% for semaglutide).

Can I switch from Mounjaro to Zepbound or vice versa? Yes, with no dose adjustment needed. If you are on Mounjaro 10 mg and switch to Zepbound 10 mg, you continue at 10 mg. The products are interchangeable at equivalent doses. The switch usually occurs due to insurance authorization changes or pharmacy supply issues.

Does the brand name affect side effects? No. Side effects (nausea, reflux, constipation, injection site reactions) are caused by the tirzepatide molecule, not the brand label. Mounjaro, Zepbound, and compounded tirzepatide have identical side-effect profiles at equivalent doses.

Which brand name is better, Mounjaro or Zepbound? Neither is pharmacologically superior. The "better" choice depends on your insurance coverage, diagnosis, and out-of-pocket cost. For diabetes patients with insurance coverage, Mounjaro is usually better. For weight-loss patients without coverage, compounded tirzepatide is usually better due to cost.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. NEJM. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
7. Radley DC et al. Off-label prescribing among office-based physicians. Pharmacotherapy. 2006.
8. Patel M et al. Quality assessment of compounded semaglutide products from U.S. pharmacies. Journal of Pharmaceutical Sciences. 2024.
9. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
10. CoverMyMeds Prior Authorization Database. Tirzepatide prior authorization approval rates by indication. 2025.
11. Eli Lilly and Company. Mounjaro prescribing information. Revised November 2023.
12. Eli Lilly and Company. Zepbound prescribing information. Revised November 2023.
13. U.S. Patent and Trademark Office. Patent No. 9,255,154: GIP/GLP-1 receptor co-agonists. Issued February 2016.
14. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Section 1860D-2(e)(2)(A): Exclusion of coverage for weight-loss medications.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Botox is a registered trademark of Allergan. Viagra and Revatio are registered trademarks of Pfizer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.